AstraZeneca strengthens innovation partnership in India
Following the signature of the bilateral innovation partnership for a sustainable future between Sweden and India, AstraZeneca announces an investment of USD 90 million in India over the next 5 yearsto develop local skills, build scientific innovation and promote quality manufacturing with the aim to improve overall health outcomes in the country
17th April2018:Leading global science-led biopharmaceutical company AstraZeneca todayannounced its decision of further investing $ 90 million over the next 5 yearsin India. The announcement was made following a meeting between the company’sExecutive Vice President for International Region –Mr. Leon Wang and HonorablePrime Minister of India, Shri Narendra Modi, during the latter’s visit toSweden, where the two countries signed a joint declaration on innovation partnershipfor a sustainable future.
This investment commitmentwill span across AstraZeneca’s diverse footprint in Indiawith an aim to strengthenits manufacturing, clinical operations, patient safety & regulatory science,IT services and commercial operations. Furthermore, thisinvestment will support scientific data generation, quality manufacturing,science talent development and collaborative development of innovativesolutions to improve the standard of care of non-communicable diseases inIndia. The commitment also aligns closely with the Indian government’sinitiatives to create a stronger business, innovation, and healthcareenvironment such as “Skill India”, “National Health Policy” and “AyushmanBharat.”
Leon Wang, Executive Vice President for InternationalRegion, AstraZeneca, said“AstraZenecahas a long-standing commitment in India of 40 years. Our latest investmentreflects our commitment to address the unmet needs in non-communicable diseases,enable high-value job creation andboost medical innovation in the country. Webelieve, this investment commitment across AstraZeneca’s business footprint inIndia, will make a positive impact. It also aligns closely with the government’svision for healthcare and innovation.”
AstraZeneca’s strategyin India is to address the growing burden of non-communicable diseases. Thecompany invests in many initiatives and programs such as the Young Health Programme, Earlyaction in Diabetes & Healthy Lung for early action in awareness,prevention, detection and holistic management of non-communicable diseases.
At present, AstraZeneca has a workforce of over 4000employees in India spanning manufacturing, sales and marketing, clinicaloperations, IT services, digital services and Global medicines development. Thecompany recently announced expansion of its Global Technology Centre (GTC) inChennai, now employing more than 2000 employee is AstraZeneca’s first,in sourced IT facility. AstraZeneca’s manufacturing facility in Bengaluru has asophisticated production facility designed to meet the most stringentinternational standards, conforming to World Health Organisation cGMP (currentGood Manufacturing Practices) norms. AstraZeneca also has a sizeable clinicaloperation and is expanding its Global medicines development unit that focuseson patient safety and regulatory science in India.